WALTHAM, MA--(Marketwire - July 15, 2008) - EyeGate Pharma, a privately held specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics into the front and back of the eye to treat serious ocular diseases, today announced the initiation of patient dosing in a prospective, multi-center, randomized, double-masked U.S. Phase II proof-of-concept study of the EyeGate® II Ocular Drug Delivery System. This landmark Phase II proof-of-concept study of EGP-437 and the EyeGate® II represents the first U.S. study under an open IND to employ iontophoresis technology to deliver an active compound into the eye.
